Invitation to the presentation of Bactiguard’s interim report on August 13, 2020
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday August 13, 2020 at 7:30 CET.
In connection with this, a webcast for investors, analysts and media will be held at 10:00 CET on August 13. CEO Cecilia Edström will present the interim report and answer questions. Bactiguard's new CFO Gabriella Caracciolo will also participate.
The report and a presentation for the webcast will be available at Bactiguard’s website www.bactiguard.com.
To participate in the webcast, please use this link:
https://tv.streamfabriken.com/bactiguard-q2-2020
To participate only by conference call, dial:
SE: +46850558366, UK: +443333009266, US: +18332498407
Questions can be asked either in writing via the webcast or orally if you attend the conference call.
For further information, please contact:
Cecilia Edström, CEO, phone: +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags: